Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.69 |
| ▸ | APP | P05067 | 2/20 | 0.66 |
| ▸ | RXRA | P19793 | 1/20 | 0.62 |
| ▸ | RXRB | P28702 | 1/20 | 0.62 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.59 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 2/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA7 | P43166 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11853239 | 0.92 | APP (0.62) | MAOBAPPRXRARXRBFFAR1 | |
| SCHEMBL228292 | 0.91 | LMNA (0.67) | MAOBAPPRXRARXRBFFAR1 | |
| SCHEMBL4953 | 0.89 | LMNA (0.64) | MAOBAPPRXRARXRBFFAR1 | |
| SCHEMBL2399080 | 0.89 | APP (0.80) | MAOBAPPRXRARXRBFFAR1 | |
| SCHEMBL850999 | 0.89 | APP (0.78) | MAOBAPPFFAR1MAOALMNA | |
| SCHEMBL11839266 | 0.88 | APP (0.62) | MAOBAPPRXRARXRBFFAR1 | |
| SCHEMBL8616107 | 0.86 | MCL1 (0.60) | MAOBAPPRXRARXRBFFAR1 | |
| SCHEMBL7665986 | 0.86 | MCL1 (0.60) | MAOBAPPRXRARXRBFFAR1 | |
| SCHEMBL12717358 | 0.86 | LMNA (0.60) | MAOBAPPRXRARXRBFFAR1 | |
| SCHEMBL10609652 | 0.84 | LMNA (0.75) | MAOBAPPFFAR1FFAR4MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595243-B2 | Modulators of extracellular signal-regulated kinase | GEN1E LIFESCIENCES INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20250136571-A1 | MODULATORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE | GEN1E LIFESCIENCES INC. | 2025-05-01 | — | — | US | disclosed |
| WO-2025085745-A1 | MODULATORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE | GEN1E LIFESCIENCES INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| US-9856252-B2 | 2-(hetero)aryl-benzimidazole and imidazopyridine derivatives as inhibitors of asparagime emethyl transferase | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2018-01-02 | — | — | US | disclosed |
| EP-2958898-B1 | 2-(HETERO)ARYL-BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF ASPARAGIME EMETHYL TRANSFERASE | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2017-07-19 | — | — | EP | disclosed |
| CN-103124750-B | Photoreactive polymer and alignment layer including the same | 株式会社LG化学 | 2017-02-15 | — | — | CN | disclosed |
| US-20160222005-A1 | 2-(HETERO)ARYL-BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF ASPARAGIME EMETHYL TRANSFERASE | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2016-08-04 | — | — | US | disclosed |
| US-20160222005-A1 | 2-(HETERO)ARYL-BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF ASPARAGIME EMETHYL TRANSFERASE | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2016-08-04 | — | — | US | disclosed |
| WO-2015087094-A1 | NEW ARYLALKENYLPROPARGYLAMINE DERIVATIVES EXHIBITING NEUROPROTECTIVE ACTION FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SEMMELWEIS EGYETEM (HU) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015087094-A1 | NEW ARYLALKENYLPROPARGYLAMINE DERIVATIVES EXHIBITING NEUROPROTECTIVE ACTION FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SEMMELWEIS EGYETEM (HU) | 2015-06-18 | — | — | WO | disclosed |
| EP-0770065-B1 | TRI-SUBSTITUTED PHENYL DERIVATES USEFUL AS PDE IV INHIBITORS | CELLTECH R&D LTD (GB) | 2004-03-31 | — | — | EP | disclosed |
| US-6077854-A | Tri-substituted phenyl derivatives and processes for their preparation | CELLTECH THERAPEUTICS, LIMITED (GB) | 2000-06-20 | — | — | US | disclosed |
| EP-0596057-B1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS | ZENECA LTD (GB) | 1998-09-09 | — | — | EP | disclosed |
| US-5786354-A | Tri-substituted phenyl derivatives and processes for their preparation | CELLTECH THERAPEUTICS, LIMITED (GB) | 1998-07-28 | — | — | US | disclosed |
| CN-1151732-A | Tri-substituted phenyl derivates useful as PDE IV inhibitors | CELLTECH THERAPEUTICS LTD (GB) | 1997-06-11 | — | — | CN | disclosed |
| EP-0770065-A1 | TRI-SUBSTITUTED PHENYL DERIVATES USEFUL AS PDE IV INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1997-05-02 | — | — | EP | disclosed |
| WO-1995035281-A1 | TRI-SUBSTITUTED PHENYL DERIVATES USEFUL AS PDE IV INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1995-12-28 | — | — | WO | disclosed |
| EP-0394906-B1 | Liquid crystalline composition | MERCK PATENT GMBH (DE) | 1995-12-20 | — | — | EP | disclosed |
| EP-0596057-A1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS | ZENECA LIMITED (GB) | 1994-05-11 | — | — | EP | disclosed |
| WO-1993021183-A1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS | ZENECA LIMITED (GB) | 1993-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136571-A1 | MODULATORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE | MAP3K20, MAP3K6, CDC42BPG | MAOB 3363/4885APP 4345/4885RXRA 1823/4885 |
| US-20160222005-A1 | 2-(HETERO)ARYL-BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF ASPARAGIME EMETHYL TRANSFERASE | B2M, HBG2, BCAT2 | MAOB 1214/4885APP 4792/4885RXRA 3472/4885 |
| US-12595243-B2 | Modulators of extracellular signal-regulated kinase | CDC42BPG, GRK3, ERBB2 | MAOB 3970/4885APP 4808/4885RXRA 1372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.